Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

Summary

Randomized, multicenter, double-blind, double-dummy, active-controlled, parallel-design study in approximately 201 postmenopausal women. A subset of subjects (approximately 102) will also participate in a pharmacokinetic (PK) component of the study. Each subject will be randomized to 1 of 3 treatment regimens for 3 months.

Timeline

Start

2009-05

Primary completion

2009-10

Completion

2009-10

Drugs

Indications